Products
Anzurstobart Biosimilar Monoclonal Antibody (SIRPα) for Research
Cat No.: GMP-Bios-INN-1083
Anti-SIRPA therapeutic antibody (Pre-made Anzurstobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Anzurstobart (development code BMS-986351) is a monoclonal antibody targeting SIRPA. It is developed by Celgene Corporation for acute myeloid leukaemia, myelodysplastic syndromes. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1083-1mg | 1mg | 3090 |
| GMP-Bios-INN-1083-10mg | 10mg | |
| GMP-Bios-INN-1083-100mg | 100mg | |
| GMP-Bios-INN-1083-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Anzurstobart biosimilar, Whole mAb, Anti-SIRPA Antibody: Anti-SIRP Alpha/CD172a/SIRPA/Tyrosine-protein phosphatase non-receptor type substrate 1 therapeutic antibody |
| INN Name | Anzurstobart |
| Target | SIRPA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | 7st5:HL:hl |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Celgene Corporation |
| Conditions Approved | na |
| Conditions Active | Acute myeloid leukaemia;Myelodysplastic syndromes |
| Conditions Discontinued | Non-Hodgkin's lymphoma;Solid tumours |
| Production | na |
| Development Tech | na |
